Impilo AI provides a cloud‑based platform that integrates curated African genomic, proteomic and biobank data with machine‑learning models to automate drug‑discovery workflows. The system delivers AI‑driven target identification, generative chemistry, variant‑aware molecular docking and population‑specific ADMET predictions, and supports real‑time collaboration and API‑based export for research teams developing treatments for African diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Researchers and pharmaceutical developers targeting diseases prevalent in African populations face limited access to high‑performance computational tools, fragmented genomic data, and high costs, resulting in prolonged discovery timelines and low success rates for viable drug candidates.
Solution
Impilo AI offers a cloud‑based platform that combines state‑of‑the‑art machine‑learning models with curated African omics datasets to automate key stages of drug discovery. The system performs AI‑driven target identification, generative chemistry for novel molecule design, and high‑precision molecular docking that accounts for African genetic variants. Integrated ADMET prediction models, trained on population‑specific data, provide early safety and efficacy assessments. Researchers can collaborate in real‑time through shared workspaces, while results are securely stored and exported via standard APIs for downstream development.
Target Audience
The primary customers are academic research groups, biotech startups, and pharmaceutical R&D teams in Africa focused on malaria, tuberculosis, and other neglected tropical diseases.
Features
- African omics integration: curated genomic, proteomic, and biobank data from across the continent feed population‑specific machine‑learning models.
- AI‑powered target identification: deep‑learning algorithms predict protein structures and prioritize disease‑relevant targets using African variant information.
- Generative chemistry engine: produces novel chemical scaffolds optimized for selected targets, incorporating synthetic feasibility constraints.
- Molecular docking with variant analysis: high‑throughput docking pipelines evaluate binding affinity against African protein isoforms.
- ADMET prediction models trained on African population data to improve early toxicity and pharmacokinetic forecasts.
- Cloud‑native collaborative workspace: real‑time project sharing, version control, and computational resource scaling for teams of any size.
- Secure data management: end‑to‑end encryption, role‑based access controls, and compliance with data‑privacy regulations.
- API and export tools: FHIR‑compatible endpoints and standard file formats enable integration with existing drug‑development pipelines.